Drugs / EPI-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07618195 | Jan 2026 → Jun 2028 expected | androgenetic alopecia | Epibiotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPI-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07618195 ↗ |
| Modality | Cell therapy | “EPI-001 is an autologous dermal papilla cell-based investigational product administered by subcutaneous injection to the scalp for the treatment of androgenetic alopecia.” NCT07618195 ↗ |
| Route | Subcutaneous | “administered by subcutaneous injection” NCT07618195 ↗ |